Factors associated with results and conclusions of trials of thiazolidinediones

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Rattinger, Gail ^a   Bero, Lisa ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHOLESTEROL; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE; 2,4-THIAZOLIDINEDIONE; INSULIN;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DRUG INDUSTRY; FINANCIAL MANAGEMENT; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INFORMATION PROCESSING; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PEER REVIEW; POSTPRANDIAL STATE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SYSTEMATIC ERROR; TREATMENT OUTCOME; METABOLISM; REGRESSION ANALYSIS;

CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RESEARCH DESIGN; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 67149129945     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005826     Document Type: Article

References (45)

1. Bero LA, Rennie D (1996) Influences on the quality of published drug studies. Int J Technol Assess Health Care 12: 209-237.
2. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, et al. (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163: 185-194.
3. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 291: 2457-2465.
4. Dickersin K (1990) The existence of publication bias and risk factors for its occurrence. JAMA 263: 1385-1389.
5. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326: 1167-1170.
6. Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289: 454-465.
7. Cho MK, Bero LA (1996) The quality of drug studies published in symposium proceedings. Ann Intern Med 124: 485-489.
8. Kjaergard LL, Als-Nielsen B (2002) Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 325: 249.
9. Chalmers TC, Block JB, Lee S (1972) Controlled studies in clinical cancer research. N Engl J Med 287: 75-78.
10. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408-412.
11. Djulbegovic B, Lacevic M, Cantor A, Fileds KK, Bennett CL, et al. (2000) The uncertainty principle and industry-sponsored research. Lancet 356: 635-638.
12. Barnes DE, Bero LA (1998) Why review articles on the health effects of passive smoking reach different conclusions. JAMA 279: 1566-1570.
13. Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med 4: e184.
14. Nathan DM (2007) Finding new treatments for diabetes-how many, how fast... how good? N Engl J Med 356: 437-440.
15. CDC (2007) Centers for Disease Control and Prevention. National Diabetes Surveillance System. Vol (Accessed February 28, 2007, at http:// www.cdc.gov/diabetes/statistics).
16. Nathan DM (2002) Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347: 1342-1349.
17. Holmboe ES (2002) Oral antihyperglycemic therapy for type 2 diabetes: clinical applications. JAMA 287: 373-376.
18. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH (2006) Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev. CD006060.
19. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH (2007) Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev. CD006063.
20. Rosiglitazone Full Prescribing Information 2007. Available at:http:// www.fda.gov/cder/foi/label/2007/021071s031lbl.pdf. Accessed October 6, 2008.
21. Pioglitazone Full Prescribing Information October 6, 2008. Available at: http://www.fda.gov/cder/drug/infopage/pioglitazone/ pioglitazone_label20070814.pdf. Accessed October 6, 2008.
22. Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287: 360-372.
23. HHS (2007) Rezulin to be withdrawn from the market. (Acessed March 20, 2007, at http://www.fda.gov/bbs/topics/NEWS/NEW00721.html). In: News. UDoHaHSH, ed.
24. Chiquette E, Ramirez G, Defronzo R (2004) A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164: 2097-2104.
25. Ioannidis JP, Cappelleri JC, Sacks HS, Lau J (1997) The relationship between study design, results, and reporting of randomized clinical trials of HIV infection. Control Clin Trials 18: 431-444.
26. Ioannidis JP, Polycarpou A, Ntais C, Pavlidis N (2003) Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time. Eur J Cancer 39: 2278-2287.
27. (2006) Institute for Scientific Information. Philadelphia, PA: Institute for Scientific Information.
28. Chalmers I, Adams M, Dickersin K, Hetherington J, Tarnow-Mordi W, et al. (1990) A cohort study of summary reports of controlled trials. JAMA 263: 1401-1405.
29. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G (2005) Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 21: 167-174.
30. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27: 141-147.
31. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, et al. (2005) Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med 22: 980-985.
32. Ramachandran A, Snehalatha C, Salini J, Vijay V (2004) Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes-a study in Indians. J Assoc Physicians India 52: 459-463.
33. Ko GT, Tsang PC, Wai HP, Kan EC, Chan HC (2006) Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial. Adv Ther 23: 799-808.
34. Derosa G, Gaddi AV, Ciccarelli L, Fogari E, Ghelfi M, et al. (2005) Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. J Int Med Res 33: 284-294.
35. Perriello G, Pampanelli S, Di Pietro C, Brunetti P (2006) Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabet Med 23: 246-252.
36. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP (2004) Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 27: 41-46.
37. Isa SH, Najihah I, Nazaimoon WM, Kamarudin NA, Umar NA, et al. (2006) Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control. Diabetes Res Clin Pract 72: 48-52.
38. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443.
39. Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, et al. (2004) Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 27: 1324-1329.
40. Umpierrez G, Issa M, Vlajnic A (2006) Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 22: 751-759.
41. Yu D, Murdoch SJ, Parikh SJ, Marcovina SM, Cobitz A, et al. (2006) Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diab Vasc Dis Res 3: 189-196.
42. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioanndis JP, et al. (2002) Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 287: 2973-2982.
43. Krimsky S, Rothenberg LS (2001) Conflict of interest policies in science and medical journals: editorial practices and author disclosures. Sci Eng Ethics 7: 205-218.
44. Buchkowsky SS, Jewesson PJ (2004) Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 38: 579-585.
45. Patsopoulos NA, Ioannidis JP, Analatos AA (2006) Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ 332: 1061-1064.